Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus docetaxel or pemetrexed versus docetaxel or pemetrexed as second-line treatment for advanced EGFR wild-type non-squamous non-small cell lung cancer
ChiCTR-IIR-17014127Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Nov 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib, docetaxel and pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: progression-free survival. Started Nov 2017; status: recruiting.
02
Drugs
Rivoceranibdocetaxelpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-IIR-17014127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17014127.